<!DOCTYPE html>
<!-- saved from url=(0065)https://bestpractice.bmj.com/topics/en-gb/151/management-approach -->
<html class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>Non-ST-elevation myocardial infarction - Approach | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="apple-itunes-app" content="app-id=1105379489">
      <meta name="description" content="Part of the acute coronary syndrome spectrum. Usually caused by a partial or near-complete occlusion of a coronary artery resulting in compromised blood flow to myocardium with subsequent myocardial injury or infarction as demonstrated by elevation in troponin. There are differences in typical pr...">
      <meta name="author" content="Cody S. Deen">
      <!-- Optimize Page Hiding Snippet --> 
      <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="./151_NSTEMI_management_recommendations_files/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="./151_NSTEMI_management_recommendations_files/414393182248444" async=""></script><script async="" src="./151_NSTEMI_management_recommendations_files/fbevents.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_recommendations_files/analytics.js"></script><script async="" src="./151_NSTEMI_management_recommendations_files/get-loader.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_recommendations_files/insight.min.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_recommendations_files/js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_recommendations_files/uwt.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_recommendations_files/4896.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_recommendations_files/analytics.js"></script><script async="" src="./151_NSTEMI_management_recommendations_files/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': "id6370964",
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"},{"name":"bmj.com:registrant"},{"name":"bp-institutional-users:registrant"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script>
      <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script>
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/151/management-approach">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/151/management-approach">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/151/management-approach">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/151/management-approach">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/151/management-approach">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/151/management-approach">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/151/management-approach">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/151/management-approach">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/151/management-approach">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/151/management-approach">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/151/management-approach">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/151/management-approach">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/151/management-approach">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/151/management-approach">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/151/management-approach">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/151/management-approach">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/151/management-approach">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach">
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script>
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <meta name="msvalidate.01" content="76FD53F39FDFB050A93D7925608BA016">
      <style type="text/css">._6772342E312E39_src-lib-Adapter-styles__centerStyle--2U8wI, ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M, ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio, ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         top: 50%;
         position: absolute;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         box-sizing: border-box;
         padding: 0;
         border-radius: 3px;
         position: fixed;
         display: block;
         visibility: visible;
         bottom: 0;
         background-color: #f3f3f3;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, -webkit-transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out, -webkit-transform 0.1s 0s ease-in-out;
         z-index: 99999;
         box-shadow: 0px 0px 5px 1px rgba(0, 0, 0, 0.18);
         overflow: hidden;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dragging--2uZno {
         transition: opacity 0.1s 0s linear;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__closed--eHbpJ {
         visibility: hidden;
         opacity: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__loading--1ewAG {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         position: relative;
         height: 35px;
         line-height: 35px;
         min-width: 165px;
         text-align: center;
         cursor: move;
         z-index: 11;
         overflow: hidden;
         font-family: Helvetica;
         font-weight: normal;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         cursor: ew-resize;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         left: 50%;
         height: 16px;
         width: 100px;
         margin-top: -8px;
         margin-left: -50px;
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 20px;
         height: 14px;
         width: 14px;
         border-radius: 8px;
         margin-top: -7px;
         display: none;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__dropdownPresence--18mrh {
         display: none;
         position: absolute;
         width: 100%;
         height: 100vh;
         }
         ._6772342E312E39_src-lib-Adapter-styles__showDropdown--242EQ {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj {
         padding: 10px 15px;
         display: block;
         cursor: pointer;
         text-decoration: none;
         text-align: left;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj:hover {
         background-color: #f5f5f5;
         }
         ._6772342E312E39_src-lib-Adapter-styles__selected--1z5-3 {
         color: #0684bd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM {
         position: relative;
         width: 160px;
         min-width: 165px;
         left: 5px;
         padding: 0;
         min-height: 30px;
         box-sizing: border-box;
         box-shadow: 0 0 4px 0 rgba(0, 0, 0, 0.2);
         background-color: #ffffff;
         border-style: solid;
         border-width: 0;
         border-top-width: 1px;
         border-bottom-width: 0px;
         border-color: #eeeeee;
         border-radius: 4px;
         font-family: "Helvetica Neue", Helvetica, Arial, sans-serif;
         font-size: 14px;
         color: #2F2F2F;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__horizontal--1DydQ {
         display: inline-flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__clickable--G0zEI {
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__noborder--1ysDv {
         border: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 10px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Offline--3PnxB {
         display: block;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Busy--IDedL {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Available--2GLYE {
         display: block;
         background-color: #32ae31;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: none;
         position: absolute;
         width: 8px;
         height: 2px;
         border-radius: 1.5px;
         background-color: #ffffff;
         -webkit-transform-origin: 50% 50%;
         transform-origin: 50% 50%;
         -webkit-transform: translate(3px, 6px);
         transform: translate(3px, 6px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__statusIcon--2SoFd {
         display: inline-block;
         position: relative;
         margin-right: 5px;
         top: 2px;
         left: 0;
         margin-top: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         box-sizing: border-box;
         height: 20px;
         width: 20px;
         margin-top: -12px;
         border-radius: 3px;
         cursor: pointer;
         border-style: solid;
         border-width: 1px;
         border-color: transparent;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw:hover {
         border-color: #cccccc;
         }
         ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 40px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         position: absolute;
         box-sizing: border-box;
         left: 3px;
         bottom: 7px;
         width: 12px;
         height: 2px;
         border: 1px solid #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         height: 12px;
         bottom: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIconBar--2WYhn {
         width: 100%;
         height: 1px;
         background-color: #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR {
         position: relative;
         overflow: hidden;
         margin: 2px;
         width: 14px;
         height: 14px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child, ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         position: absolute;
         height: 2px;
         width: 100%;
         top: 6px;
         left: 0;
         background: #888888;
         border-radius: 1px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child {
         -webkit-transform: rotate(45deg);
         transform: rotate(45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         -webkit-transform: rotate(-45deg);
         transform: rotate(-45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__contentFrame--Z6dLx {
         display: block;
         border: none;
         width: 0;
         height: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.1s 0s ease-in-out, height 0.1s 0s ease-in-out;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__ringing--2c7d0 {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         -webkit-animation-duration: 2s;
         animation-duration: 2s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: infinite;
         animation-iteration-count: infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 33px;
         margin-left: -60px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 100px;
         margin-left: -100px;
         text-overflow: ellipsis;
         overflow: hidden;
         text-align: center;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__center--3fFya, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -50px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #5FB95C;
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX:hover {
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         margin-left: -80px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #FF8800;
         color: #FF8800;
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL:hover {
         color: #FF8800;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__detectNew--2RyZg {
         background: url("https://rc-hack-new.detect");
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         top: initial !important;
         width: 300px;
         border-top-right-radius: 0;
         border-bottom-right-radius: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg {
         width: 60px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         width: 35px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         opacity: 0 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__expandable--1dLZX {
         width: 140px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         line-height: initial;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         width: 12px;
         height: 12px;
         margin-top: -6px;
         z-index: 2;
         transition: .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         -webkit-transform: translate(2px, 5px);
         transform: translate(2px, 5px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         opacity: 0;
         transition: opacity .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         z-index: 2147483648;
         top: 7px;
         position: absolute;
         left: 30px;
         height: 22px;
         width: 22px;
         display: block;
         cursor: pointer;
         opacity: 1;
         transition: .3s;
         display: flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv ._6772342E312E39_src-lib-Adapter-styles__icon--2I9x4 {
         width: 22px;
         height: 22px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         left: 7px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.2s 0s ease-in-out, height 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOutIcon--oudoy img {
         position: absolute;
         top: 3px;
         left: 1px;
         width: 14px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         display: none;
         height: 30px;
         left: 0;
         position: fixed;
         top: 0;
         -webkit-transform: opacity 0.1s 0s linear;
         transform: opacity 0.1s 0s linear;
         z-index: 999999999;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         background-color: rgba(255, 255, 255, 0.95);
         box-sizing: border-box;
         border: 1px solid #cfcfcf;
         border-radius: 4px;
         font-size: 0px;
         height: 30px;
         white-space: nowrap;
         margin: 0 0 0 5px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 img {
         vertical-align: baseline !important;
         display: inline-block !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         margin: 0 5px 0 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #cfcfcf;
         top: calc(50% - 5px);
         left: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #FF8800;
         top: calc(50% - 5px);
         left: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         border-right: none;
         border-left: 5px solid #cfcfcf;
         left: initial;
         right: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         border-right: none;
         border-left: 5px solid #fff;
         left: initial;
         right: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU {
         height: 30px;
         width: 30px;
         margin: -1px 0 0 -1px;
         vertical-align: baseline;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: none;
         position: relative;
         vertical-align: top;
         cursor: pointer;
         font-size: 18px;
         height: 28px;
         width: 28px;
         line-height: 28px;
         text-align: center;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 {
         display: none;
         width: 1px;
         height: 19px;
         margin: 5px 0;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__hack--5AVJK {
         background: url("https://rc-hack-c2d.detect");
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg {
         position: absolute;
         top: 50%;
         left: 50%;
         -webkit-transform: translateX(-50%) translateY(-50%);
         transform: translateX(-50%) translateY(-50%);
         overflow: visible !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg > path {
         fill: #0684bd;
         stroke: #0684bd;
         }
      </style>
      <style type="text/css">add-meeting-button {
         line-height: 36px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__root--3CtVK {
         margin-left: 8px;
         position: relative;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q {
         min-width: 94px;
         white-space: nowrap;
         height: 26px;
         line-height: 26px;
         padding: 0;
         font-size: 11px;
         font-weight: 500;
         text-align: center;
         color: #0684bd;
         background: #fff;
         border-radius: 20px;
         border: 1px solid #9bcee5;
         font-family: Roboto, Helvetica, Arial, sans-serif;
         font-weight: 400;
         outline: none;
         cursor: pointer;
         transition: .3s;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q:hover {
         color: #fff;
         background-color: #9bcee5;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1 {
         color: #fff;
         background-color: #c7c7c7;
         border: 1px solid #c7c7c7;
         cursor: default;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1:hover {
         cursor: default;
         background-color: #c7c7c7;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__or--Hsdgj {
         float: left;
         margin-left: 10px;
         font-size: 12px;
         color: #0684bd;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__icon--r7sAL {
         left: 5px;
         top: 4px;
         width: 18px;
         height: 18px;
         position: absolute;
         background: #fff;
         border-radius: 100%;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__text--1nLnV {
         width: 100%;
         margin-left: 25px;
         padding-right: 6px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__meetingContainer--24va2 {
         display: flex;
         flex-grow: 100;
         align-items: center;
         }
      </style>
      <style type="text/css">#rc-meeting-popup-window {
         width: 100%;
         height: 100%;
         background-color: rgba(0, 0, 0, 0.3);
         display: flex;
         justify-content: center;
         align-items: center;
         line-height: normal;
         text-align: left;
         position: fixed;
         z-index: 2147483647;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__container--2qd2O {
         width: 470px;
         height: auto;
         display: flex;
         flex-direction: column;
         align-items: stretch;
         overflow: hidden;
         box-shadow: 0 24px 38px 3px rgba(0, 0, 0, 0.14), 0 9px 46px 8px rgba(0, 0, 0, 0.12), 0 11px 15px -7px rgba(0, 0, 0, 0.2);
         border-radius: 2px;
         position: relative;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA {
         position: relative;
         width: 100%;
         height: 30px;
         line-height: 30px;
         font-size: 12px;
         box-sizing: border-box;
         background: #ffffff;
         padding-left: 15px;
         padding-top: 10px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__recurringMeetingPrompt--3U97a {
         margin: 5px 22px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X {
         position: absolute;
         top: 13px;
         right: 15px;
         color: rgba(0, 0, 0, 0.54);
         fill: rgba(0, 0, 0, 0.54);
         width: 20px;
         height: 20px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X svg {
         width: 20px;
         height: 20px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__wrapper--3DttD {
         background-color: #ffffff;
         width: 100%;
         padding: 10px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settings--15yhX {
         border-radius: 3px;
         box-sizing: border-box;
         padding: 0 8px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryLabel--2n8iQ {
         margin: 10px 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryWrapper--2LA96 {
         border-radius: 3px;
         background-color: #F9F9F9;
         border: 1px solid #E2E2E2;
         padding: 9px 16px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settingLabel--ybCle {
         display: inline-block;
         width: 80px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF {
         line-height: 20px;
         margin: 7px 0;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF * {
         vertical-align: middle;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__video--1oJss {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__audio--2dr2m {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF input:first-of-type {
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__controls--1GgrW {
         margin: 10px 0 10px 10px;
         height: 30px;
         line-height: 30px;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__schedule--3SMpg {
         background: #4285f4;
         color: #fff;
         transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
         box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14), 0 3px 1px -2px rgba(0, 0, 0, 0.12), 0 1px 5px 0 rgba(0, 0, 0, 0.2);
         border: 0;
         border-radius: 3px;
         cursor: pointer;
         display: inline-block;
         font-weight: 500;
         outline: none;
         overflow: hidden;
         text-align: center;
         z-index: 0;
         font-size: 12px;
         line-height: 30px;
         height: 32px;
         min-width: 88px;
         position: absolute;
         right: 18px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA span {
         font-size: 16px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__password--3Ij_s {
         display: none;
         margin-left: 10px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__spinner--18fX2 {
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         ._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__path--2xqMm {
         stroke-dasharray: 187;
         stroke-dashoffset: 0;
         -webkit-transform-origin: center;
         transform-origin: center;
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
      </style>
      <style></style>
   </head>
   <body class="gpw">
      <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 " style="">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
      </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-cmecpd" class="nav-item" role="menuitem">
                        <a class="nav-link" href="https://bestpractice.bmj.com/activity">CME / CPD</a>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-account" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" id="navbarDropdownMenuLink01" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        <span class="material-icons"></span>&nbsp;
                        <span>stailor@bmj.com</span> 
                        <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-account-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink01">
                           <span class="material-icons"></span>
                           <ul class="list-group" role="menu">
                              <li class="dropdown-item">
                                 <form method="POST" action="https://bestpractice.bmj.com/logout">
                                    <input type="hidden" name="loggedIn" id="loggedIn" value="true">
                                    <button type="submit" value="Log out">
                                    Log out
                                    </button>
                                 </form>
                              </li>
                              <li class="dropdown-item"><a href="https://myaccount.bmj.com/myaccount/account/home-view.html?fwdUrl=https://bestpractice.bmj.com" target="_blank">My details</a></li>
                              <li hidden="hidden" class="dropdown-item"><a href="https://myaccount.bmj.com/myaccount/account/home-view.html#email-matrix-container?fwdUrl=https://bestpractice.bmj.com" target="_blank">My emails</a></li>
                           </ul>
                        </div>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            <!-- These are required in completion, see BP-232 -->
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script><script type="text/javascript" id="">var meta=document.createElement("meta");meta.name="msvalidate.01";meta.content="76FD53F39FDFB050A93D7925608BA016";document.getElementsByTagName("head")[0].appendChild(meta);</script>
      <main id="tmp" class="container tmp tmp-basic main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 151; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/151" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/151">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/151">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/151">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>Non-ST-elevation myocardial infarction</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/pdf/151.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 208px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 208px;">
                  <ul id="menus" role="menubar">
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-0">
                           <li><a href="151_NSTEMI_overview_summary.html" id="Summary">Summary</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-1">
                           <li><a href="151_NSTEMI_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/aetiology" id="Aetiology">Aetiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/case-history" id="Case history">Case history</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-2">
                           <li><a href="151_NSTEMI_diagnosis_recommendations.html" id="Recommendations">Recommendations</a></li>
                           <li><a href="151_NSTEMI_diagnosis_hisotry_and_exam.html" id="History and exam">History and exam</a></li>
                           <li><a href="151_NSTEMI_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/differentials" id="Differentials">Differentials</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/criteria" id="Criteria">Criteria</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-3">
                           <li><a href="151_NSTEMI_management_recommendations.html" class="active" id="Recommendations">Recommendations</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm" id="Treatment algorithm">Treatment algorithm</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/prevention" id="Prevention">Prevention</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/patient-discussions" id="Patient discussions">Patient discussions</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-4">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/monitoring" id="Monitoring">Monitoring</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/complications" id="Complications">Complications</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/prognosis" id="Prognosis">Prognosis</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-5">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/guidelines" id="Guidelines">Guidelines</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/images-and-videos" id="Images and videos">Images and videos</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/references" id="References">References</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/patient-leaflets" id="Patient leaflets">Patient leaflets</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/calculators" id="Calculators">Calculators</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/evidence" id="Evidence">Evidence</a></li>
                        </ul>
                     </li>
                     <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/151/pdf/151.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
                  </ul>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Approach</h2>
         <div class="card">
            <div class="card-block">
               <section>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The following management approach should be applied to patients with acute coronary syndrome NSTEMI (type 1 NSTEMI). Ideal treatments of the other types of NSTEMI are currently evolving and are beyond the scope of this topic.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The aim of initial assessment is to relieve pain, identify and treat life-threatening instability, and then admit the patient for further treatment/observation.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     The goal of treatment is to relieve ischaemia, prevent further thrombosis or embolism, and correct haemodynamic abnormalities. All patients should undergo early risk estimation based on the medical history, physical examination, ECG findings, and cardiac markers.
                  </p>
               </section>
               <section>
                  <h3>Initial management</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Initial medical therapy is indicated in all patients, with variation in some choices of agent according to risk stratification.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Oxygen
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     All patients require oxygen saturation measurement using pulse oximetry.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     Guidelines recommend supplemental oxygen therapy only in patients who are hypoxaemic (arterial oxygen saturation &lt;90%), or in those who have respiratory distress or other high-risk features for hypoxaemia.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                     <span class="citationText" aria-hidden="true">Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/37/3/267/2466099
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26320110?tool=bestpractice.com
                     </span>
                     </span>
                     Liberal use of oxygen is associated with increased mortality in patients with acute coronary syndrome.
                     <span class="reference">
                        <a href="#referencePop53" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[53]</a> 
                        <span class="citationText" aria-hidden="true">
                           Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131)
                           <rc-c2d-number data-rc-number=":1693-705">:1693-705</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/29726345?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop54" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[54]</a> 
                     <span class="citationText" aria-hidden="true">Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018 Oct 24;363:k4169.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.bmj.com/content/363/bmj.k4169.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/30355567?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Antiplatelet therapy
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Aspirin is indicated immediately for all patients suspected of having an acute coronary syndrome unless contraindicated or already taken.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     Healthcare personnel providing pre-hospital emergency services should similarly give aspirin (chewed) to chest pain patients suspected of having an acute coronary syndrome, again unless contraindicated or already taken by the patient.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     Aspirin should be continued at a daily maintenance dose thereafter.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_1" name="evidence-score-1" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#popuplink-ref-score_1" data-original-title="">
                        Evidence A
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Reduction in mortality: there is good-quality evidence that antiplatelet treatment (aspirin 75-325 mg/day) reduces the risk of death, MI, and stroke compared with placebo in people with unstable angina. The evidence suggests no added cardiovascular benefit, but possible added harm, from doses of aspirin &gt;325 mg daily.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                        </span>
                     </span>
                     Aspirin, an irreversible COX-1 inhibitor, suppresses thromboxane A2 production preventing platelet aggregation, and reduces the incidence of death and non-fatal myocardial infarction (MI) in patients with unstable angina
                     <span class="reference"> 
                     <a href="#referencePop55" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[55]</a> 
                     <span class="citationText" aria-hidden="true">Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396-403.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/6135989?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop56" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[56]</a> 
                     <span class="citationText" aria-hidden="true">Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369-75.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/3903504?tool=bestpractice.com
                     </span>
                     </span>
                     or acute MI.
                     <span class="reference"> 
                     <a href="#referencePop56" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[56]</a> 
                     <span class="citationText" aria-hidden="true">Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369-75.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/3903504?tool=bestpractice.com
                     </span>
                     </span>
                     Aspirin has been shown to achieve a 30% to 51% reduction in future coronary events.
                     <span class="reference"> 
                     <a href="#referencePop57" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[57]</a> 
                     <span class="citationText" aria-hidden="true">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.bmj.com/content/324/7329/71.full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/11786451?tool=bestpractice.com
                     </span>
                     </span>
                     High-dose aspirin is associated with an increased risk of bleeding when compared with low-dose aspirin in the absence of improved outcomes.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Similarly, P2Y12 receptor inhibitors (e.g., clopidogrel, ticagrelor, prasugrel) are indicated in early hospital medical treatment of NSTEMI, providing powerful tools against platelet adhesion, activation, and aggregation. P2Y12 receptor inhibitors can reduce mortality and morbidity, but they are associated with an increased risk of bleeding.
                     <span class="reference">
                        <a href="#referencePop58" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[58]</a> 
                        <span class="citationText" aria-hidden="true">
                           Motovska Z, Kala P. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Clin Ther. 2008;30 Pt 2
                           <rc-c2d-number data-rc-number=":2191-202">:2191-202</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19281914?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop59" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[59]</a> 
                     <span class="citationText" aria-hidden="true">Squizzato A, Bellesini M, Takeda A, et al. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev. 2017 Dec 14;(12):CD005158.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005158.pub4/full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/29240976?tool=bestpractice.com
                     </span>
                     </span>
                     Ticagrelor and prasugrel are newer P2Y12 agents, which trials have shown to have a faster onset of action and greater efficacy compared with clopidogrel.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop60" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[60]</a> 
                     <span class="citationText" aria-hidden="true">Mahaffey KW, Held C, Wojdyla DM, et al; PLATO Investigators. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22;63(15):1493-9.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24561148?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop61" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[61]</a> 
                     <span class="citationText" aria-hidden="true">Pollack CV Jr, Davoudi F, Diercks DB, et al; PLATO Investigators. Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol. 2017 Jun;40(6):390-8.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://onlinelibrary.wiley.com/doi/full/10.1002/clc.22733
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/28598510?tool=bestpractice.com
                     </span>
                     </span>
                     However, the risk of bleeding is also greater with these two P2Y12 agents compared with clopidogrel.
                     <span class="reference"> 
                     <a href="#referencePop62" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[62]</a> 
                     <span class="citationText" aria-hidden="true">Varenhorst C, Alström U, Braun OÖ, et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014 Nov;100(22):1762-9.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24957530?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop63" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[63]</a> 
                     <span class="citationText" aria-hidden="true">Bavishi C, Panwar S, Messerli FH, et al. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2015 Sep 1;116(5):809-17.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26119655?tool=bestpractice.com
                     </span>
                     </span>
                     All patients should be given dual antiplatelet therapy with a P2Y12 receptor inhibitor in addition to aspirin. If the patient is intolerant of aspirin or it is otherwise contraindicated, a P2Y12 receptor inhibitor can be given instead of aspirin, but two different P2Y12 receptor inhibitors should not be given together. Clopidogrel or ticagrelor are suitable for patients on either non-invasive or invasive strategies, while prasugrel is recommended only for patients on an invasive strategy since existing data come from patients treated by percutaneous interventions.
                     <span class="reference"> 
                     <a href="#referencePop64" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[64]</a> 
                     <span class="citationText" aria-hidden="true">O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009 Aug 18;54(8):678-85.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19679245?tool=bestpractice.com
                     </span>
                     </span>
                     There are variable responses to antiplatelet inhibition with clopidogrel based on loss-of-function alleles for the CYP219C enzyme, which is required to convert clopidogrel to its active drug metabolite. The presence of at least one loss-of-function mutation for CYP219C may be as high as 30% in some populations. In a single-centre, retrospective study of clopidogrel resistance it appeared that patients with clopidogrel resistance who remain on clopidogrel are at a 4-fold increase for major adverse cardiovascular or cerebrovascular events compared with those placed on a different P2Y12 inhibitor.
                     <span class="reference"> 
                     <a href="#referencePop65" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[65]</a> 
                     <span class="citationText" aria-hidden="true">Lee CR, Sriramoju VB, Cervantes A, et al. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circ Genom Precis Med. 2018 Apr;11(4):e002069.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/29615454?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Clinicians need to tailor therapy to strike a balance between a newer agent that may have a faster onset of action and greater antiplatelet effect, but could potentiate bleeding (especially in those with prior TIA or stroke). Regardless of which P2Y12 receptor inhibitor is chosen, a loading dose should be given as soon as possible in most patients and then a maintenance dose continued for a minimum of 12 months.
                     <span class="reference">
                        <a href="#referencePop66" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[66]</a> 
                        <span class="citationText" aria-hidden="true">
                           Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 7;372(19)
                           <rc-c2d-number data-rc-number=":1791-800">:1791-800</rc-c2d-number>
                           .
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        https://www.nejm.org/doi/full/10.1056/NEJMoa1500857
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/25773268?tool=bestpractice.com
                        </span>
                     </span>
                     Note that P2Y12 receptor inhibitors should not be given if urgent coronary artery bypass graft (CABG) is anticipated or planned within 5 to 7 days, so it may be necessary to delay starting a P2Y12 receptor inhibitor until diagnostic angiography clarifies whether early CABG is indicated. For patients receiving chronic clopidogrel therapy prior to presentation, there is some evidence to suggest decreased periprocedural MI with clopidogrel reloading at the time of percutaneous coronary intervention (PCI).
                     <span class="reference"> 
                     <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                     <span class="citationText" aria-hidden="true">Patti G, Pasceri V, Mangiacapra F, et al; ARMYDA-8 RELOAD-ACS Investigators. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet Therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial). Am J Cardiol. 2013 Jul 15;112(2):162-8.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/23601577?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Pain relief
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Pain relief is indicated in the initial management of all patients. Sublingual glyceryl trinitrate (GTN) reduces myocardial oxygen demand and enhances myocardial oxygen delivery. GTN is contraindicated if there is a history of recent phosphodiesterase-5 inhibitor use (e.g., sildenafil); it should not be given if systolic BP is &lt;90 mmHg or there is a concern about right ventricular infarction. Intravenous GTN is recommended in patients with no symptom relief after 3 sublingual GTN tablets or sprays taken 5 minutes apart.
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_2" name="evidence-score-2" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#popuplink-ref-score_2" data-original-title="">
                        Evidence C
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Reduction in chest pain episodes: there is poor-quality evidence that glyceryl trinitrate reduces episodes of chest pain in people with unstable angina.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                        </span>
                     </span>
                     If the patient does not respond after taking 3 sublingual GTN tablets or has recurrent symptoms despite sufficient anti-ischaemic treatment, intravenous morphine can be administered in the absence of any contraindications.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     Morphine causes vasodilation and may produce reductions in heart rate (through increased vagal tone) and systolic BP to further reduce myocardial oxygen demand. It should be given instead of GTN when GTN is contraindicated. Limited data (largely observational studies) investigate morphine use for NSTEMI with evidence of potential safety concerns, thus it should be used with caution.
                     <span class="reference"> 
                     <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                     <span class="citationText" aria-hidden="true">Meine TJ, Roe MT, Chen AY, et al; CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005 Jun;149(6):1043-9.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/15976786?tool=bestpractice.com
                     </span>
                     </span>
                     One randomised, double-blind trial found that morphine delays and attenuates ticagrelor exposure and action in patients with MI.
                     <span class="reference"> 
                     <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                     <span class="citationText" aria-hidden="true">Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016 Jan 14;37(3):245-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/37/3/245/2467204
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26491112?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Beta-blockers
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Oral beta-blockers are recommended for routine use in all patients unless contraindicated.
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_3" name="evidence-score-3" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#popuplink-ref-score_3" data-original-title="">
                        Evidence C
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Reduction in mortality: there is poor-quality evidence that propranolol reduces mortality, MI, and requirement for CABG or percutaneous coronary interventions at 30 days compared with placebo in people with unstable angina who are taking optimal doses of nitrates and nifedipine.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                        </span>
                     </span>
                     Contraindications include heart rate &lt;60 bpm, systolic blood pressure &lt;100 mmHg, moderate or severe associated left ventricular failure, PR interval on the ECG &gt;0.24 seconds, second- or third-degree heart block, active asthma/reactive airways disease, severe COPD, right ventricular infarction, and cardiogenic shock. Randomised trials with threatened or evolving MI have shown lower rates of progression to MI with beta-blocker treatment.
                     <span class="reference"> 
                     <a href="#referencePop70" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[70]</a> 
                     <span class="citationText" aria-hidden="true">American College of Cardiology Foundation, American Health Association, Agency for Healthcare Research and Quality, et al. Fact sheet: beta-blockers for acute myocardial infarction. Apr 2005 [internet publication].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://archive.ahrq.gov/clinic/commitfact.htm
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop71" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[71]</a> 
                     <span class="citationText" aria-hidden="true">American College of Cardiology Foundation, American Health Association, Agency for Healthcare Research and Quality, et al. Practice advisory: commitment to respond to COMMIT/CCS-2 trial beta blocker use for myocardial infarction (MI) within 24 hours of hospital arrival. Apr 2005 [internet publication].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://archive.ahrq.gov/clinic/commitadvisory.htm
                     </span>
                     </span>
                     Comparative studies between the various beta-blockers in the acute setting are lacking. However, beta-blockers without intrinsic sympathomimetic activity (e.g., metoprolol, propranolol, and atenolol) are preferred. Cardioselective beta-blockers are preferred in the initial management of NSTEMI, but guidelines recommend metoprolol, bisoprolol, or carvedilol for post-NSTEMI management in patients with stabilised heart failure and reduced systolic function.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The selection of a long-term beta-blocker often depends on the clinician's familiarity with the agent. The goal resting heart rate is 50 to 60 bpm. Intravenous administration of beta-blockers has shown harm, especially for patients with evidence of heart failure or shock, and is generally avoided.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop72" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[72]</a> 
                     <span class="citationText" aria-hidden="true">Chen ZM, Pan HC, Chen YP, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1622-32.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/16271643?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Calcium-channel blockers
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Calcium-channel blockers can be given in patients with continuing or recurrent ischaemic symptoms after being given adequate nitrate and beta-blocker therapy or in those who cannot tolerate beta-blockers.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     Although they are often used, there is good-quality evidence that calcium-channel blockers are no more effective than control at reducing mortality or MI rates in people with unstable angina.
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_4" name="evidence-score-4" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#popuplink-ref-score_4" data-original-title="">
                        Evidence C
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Reduction in mortality: calcium-channel blockers are no more effective than control at reducing mortality or MI rates in people with unstable angina. Short-acting dihydropyridine calcium-channel blockers (such as nifedipine) have been associated with increased mortality in people with coronary heart disease.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                        </span>
                     </span>
                     Patients treated acutely with a calcium-channel blocker for acute angina do not need to continue these drugs, provided there is no recurrent angina on drug cessation or another indication for these drugs (i.e., hypertension). These drugs can start to be tapered after 24 hours at the discretion of the clinician. Short-acting dihydropyridines (e.g., nifedipine) should be avoided in the absence of adequate beta-blocker therapy because they may be associated with adverse outcomes.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     Verapamil or diltiazem should be avoided in severe left ventricular dysfunction.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     In the UK, use of calcium channel blockers as add-on therapy is not routine, unless beta-blockers are not tolerated or contraindicated.
                  </p>
               </section>
               <section>
                  <h3>Choice of invasive or conservative management</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Once initial management is instigated, the decision should be made as to whether the patient requires treatment using an invasive or non-invasive approach. The decision to pursue an invasive approach or medical management is made on an individual basis.
                     <span class="reference"> 
                     <a href="#referencePop73" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[73]</a> 
                     <span class="citationText" aria-hidden="true">Topol EJ. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):S123-9.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/12644350?tool=bestpractice.com
                     </span>
                     </span>
                     Guidelines recommend that high-risk patients routinely undergo early (12-24 hours) coronary angiography and angiographically directed revascularisation if possible unless patients have serious comorbidities, including cancer or end-stage liver disease, or clinically obvious contraindications, including acute or chronic (chronic kidney disease [CKD] 4 or higher) renal failure, multi-organ failure, or medical frailty.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop74" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[74]</a> 
                     <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Unstable angina and NSTEMI: early management. Nov 2013 [internet publication].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.nice.org.uk/guidance/CG94
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop75" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[75]</a> 
                     <span class="citationText" aria-hidden="true">Neumann FJ, Sousa-Uva M, Ahlsson A, et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018 Aug 25 [Epub ahead of print].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehy394/5079120
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/30165437?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">White HD, Westerhout CM, Alexander KP, et al; TRILOGY ACS investigators. Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Eur Heart J Acute Cardiovasc Care. 2016 Jun;5(3):231-42.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25897147?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop77" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[77]</a> 
                     <span class="citationText" aria-hidden="true">Wallentin L, Lindhagen L, Ärnström E, et al; FRISC-II study group. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016 Oct 15;388(10054):1903-11.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/27585757?tool=bestpractice.com
                     </span>
                     </span>
                     There has been recent evidence that early (&lt;12 hours) intervention may be more effective at reducing cardiovascular death and MI.
                     <span class="reference">
                        <a href="#referencePop78" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[78]</a> 
                        <span class="citationText" aria-hidden="true">
                           Deharo P, Ducrocq G, Bode C, et al. Timing of angiography and outcomes in high-risk patients with non-ST-segment-elevation myocardial infarction managed invasively: insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Circulation. 2017 Nov 14;136(20)
                           <rc-c2d-number data-rc-number=":1895-907">:1895-907</rc-c2d-number>
                           .
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.117.029779
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/28893843?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop79" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[79]</a> 
                     <span class="citationText" aria-hidden="true">Milosevic A, Vasiljevic-Pokrajcic Z, Milasinovic D, et al. Immediate versus delayed invasive intervention for non-STEMI patients: the RIDDLE-NSTEMI Study. JACC Cardiovasc Interv. 2016 Mar 28;9(6):541-9.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://interventions.onlinejacc.org/content/9/6/541
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26777321?tool=bestpractice.com
                     </span>
                     </span>
                     However, an increasing amount of new data, systematic reviews, and expert opinion question the benefit of routine invasive versus selective invasive approaches, especially in low-risk patients; this is an evolving field in NSTEMI.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop77" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[77]</a> 
                     <span class="citationText" aria-hidden="true">Wallentin L, Lindhagen L, Ärnström E, et al; FRISC-II study group. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016 Oct 15;388(10054):1903-11.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/27585757?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop80" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[80]</a> 
                     <span class="citationText" aria-hidden="true">Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine: endorsed by the American College of Emergency Physicians. Circulation. 2009 Jun 9;119(22):e561-87.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.109.192519
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19451357?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop81" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[81]</a> 
                     <span class="citationText" aria-hidden="true">Qayyum R, Khalid MR, Adomaityte J, et al. Systematic review: comparing routine and selective invasive strategies for the acute coronary syndrome. Ann Intern Med. 2008 Feb 5;148(3):186-96.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/18252682?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop82" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[82]</a> 
                     <span class="citationText" aria-hidden="true">Fanning JP, Nyong J, Scott IA, et al. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database Syst Rev. 2016 May 26;(5):CD004815.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004815.pub4/full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/27226069?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                     <span class="citationText" aria-hidden="true">Damman P, van Geloven N, Wallentin L, et al. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2012 Feb;5(2):191-9.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22361604?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop84" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[84]</a> 
                     <span class="citationText" aria-hidden="true">Henderson RA, Jarvis C, Clayton T, et al. 10-year mortality outcome of a routine invasive strategy versus a selective invasive strategy in non-ST-segment elevation acute coronary syndrome: the British Heart Foundation RITA-3 randomized trial. J Am Coll Cardiol. 2015 Aug 4;66(5):511-20.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26227188?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop85" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[85]</a> 
                     <span class="citationText" aria-hidden="true">Hoedemaker NP, Damman P, Woudstra P, et al; ICTUS Investigators. Early invasive versus selective strategy for non-ST-segment elevation acute coronary syndrome: the ICTUS trial. J Am Coll Cardiol. 2017 Apr 18;69(15):1883-93.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/69/15/1883
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/28408018?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Guidelines recommend that an invasive approach is appropriate if any of the following high-risk features are present:
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                     <span class="citationText" aria-hidden="true">Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/37/3/267/2466099
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26320110?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                     [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                     </a>
                     <span class="ccaTitle" aria-hidden="true">How do routine and selective invasive strategies compare for the treatment of unstable angina and non-ST elevation myocardial infarction?</span>
                     <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1452/full</span>
                     <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                     </span>
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Recurrent angina or ischaemia at rest or with low-level activities despite intensive medical therapy
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Rise and fall in cardiac biomarkers (troponin T or I) consistent with MI
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           New or dynamic ST-T wave changes
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Signs or symptoms of heart failure (pulmonary oedema, S3 gallop), or new or worsening mitral regurgitation
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           High-risk findings from non-invasive testing
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Haemodynamic instability
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Life-threatening arrhythmia, such as sustained ventricular tachycardia or cardiac arrest
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           PCI within 6 months
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Prior CABG
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           High-risk score (i.e., TIMI, GRACE)
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Mild to moderate renal dysfunction
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Diabetes mellitus
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Reduced left ventricular function (ejection fraction &lt;40%).
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Note that these criteria do not exactly match the risk of death stratification.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     A conservative, early medical management strategy may be appropriate in subsets of patients, especially those without the above high-risk features and with a low risk score. Guidelines and data suggest that some sub-populations do not benefit from early invasive management, and clinician discretion is advocated.
                     <span class="reference"> 
                     <a href="#referencePop74" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[74]</a> 
                     <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Unstable angina and NSTEMI: early management. Nov 2013 [internet publication].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.nice.org.uk/guidance/CG94
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop75" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[75]</a> 
                     <span class="citationText" aria-hidden="true">Neumann FJ, Sousa-Uva M, Ahlsson A, et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018 Aug 25 [Epub ahead of print].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehy394/5079120
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/30165437?tool=bestpractice.com
                     </span>
                     </span>
                     For example, a routine early invasive strategy in low-risk women with NSTEMI has not shown benefit over a conservative strategy.
                     <span class="reference"> 
                     <a href="#referencePop86" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[86]</a> 
                     <span class="citationText" aria-hidden="true">O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 2;300(1):71-80.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/18594042?tool=bestpractice.com
                     </span>
                     </span>
                     While traditionally not included in many clinical trials, emerging data suggest that older patients may benefit as much, if not more, from an invasive strategy.
                     <span class="reference"> 
                     <a href="#referencePop87" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[87]</a> 
                     <span class="citationText" aria-hidden="true">Tegn N, Abdelnoor M, Aaberge L, et al.; After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016 Mar 12;387(10023):1057-65.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26794722?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop88" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[88]</a> 
                     <span class="citationText" aria-hidden="true">Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2004 Aug 3;141(3):186-95.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/15289215?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop89" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[89]</a> 
                     <span class="citationText" aria-hidden="true">Devlin G, Gore JM, Elliott J, et al.; GRACE Investigators. Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events. Eur Heart J. 2008 May;29(10):1275-82.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/29/10/1275/464924
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/18387940?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Invasive approach</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Anticoagulation therapy (subcutaneous low molecular weight heparin [LMWH], intravenous unfractionated heparin [UFH], or the alternative agent fondaparinux) should be started on earliest recognition of NSTEMI.
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_5" name="evidence-score-5" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#popuplink-ref-score_5" data-original-title="">
                        Evidence A
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Prevention of MI: there is good-quality evidence that low molecular weight heparin reduces MI compared with unfractionated heparin in people with unstable angina. The evidence found no difference between the two treatments for major bleeds.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                        </span>
                     </span>
                     The anticoagulant is used in conjunction with antiplatelet therapy already started (i.e., aspirin and a P2Y12 receptor inhibitor). If fondaparinux is used during angiography/PCI, guidelines recommend that UFH be used in addition.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/64/24/e139
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                     </span>
                     </span>
                     Anticoagulation should not be given if there are contraindications: namely, major bleeding, or history of adverse drug reaction or heparin-induced thrombocytopenia.
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_6" name="evidence-score-6" href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#popuplink-ref-score_6" data-original-title="">
                        Evidence A
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Reduction in mortality: there is good-quality evidence that unfractionated heparin plus aspirin reduces mortality and MI at 7 days compared with aspirin alone in people with unstable angina. Longer-term follow-up suggests no difference between treatments at 12 weeks. Unfractionated heparin plus aspirin has not been associated with an increased risk of major bleeding compared with aspirin alone.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                        </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The antiplatelet and anticoagulation regimens should be started before the diagnostic angiogram (i.e., upstream). Addition of a glycoprotein IIb/IIIa inhibitor is only recommended if there is evidence of a no-reflow or a thrombotic complication.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The PCI involves angioplasty, alone or in combination with placement of a stent, capable of relieving coronary narrowing or occlusion.
                     <span class="reference"> 
                     <a href="#referencePop90" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[90]</a> 
                     <span class="citationText" aria-hidden="true">Levine GN, Bates ER, Blankenship JC, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/58/24/e44
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22070834?tool=bestpractice.com
                     </span>
                     </span>
                     Radial artery access is preferred when possible as it decreases procedural site complications.
                     <span class="reference"> 
                     <a href="#referencePop91" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[91]</a> 
                     <span class="citationText" aria-hidden="true">Vranckx P, Frigoli E, Rothenbühler M, et al; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Eur Heart J. 2017 Apr 7;38(14):1069-80.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/38/14/1069/3058512
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/28329389?tool=bestpractice.com
                     </span>
                     </span>
                     Complications of PCI include PCI-induced MI; coronary perforation, dissection, or rupture; cardiac tamponade; malignant arrhythmias; cholesterol emboli; and bleeding from the access site. Contrast-induced nephropathy is a common and potentially serious complication, especially in patients with baseline impaired renal function.
                     <span class="reference"> 
                     <a href="#referencePop92" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[92]</a> 
                     <span class="citationText" aria-hidden="true">McCullough PA, Adam A, Becker C, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 18;98(6A):5-13K.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/16949375?tool=bestpractice.com
                     </span>
                     </span>
                     Early and late stent thromboses are catastrophic complications. 
                  </p>
               </section>
               <section>
                  <h3>Conservative approach</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Anticoagulation treatment should be added to aspirin and a P2Y12 receptor inhibitor at the earliest recognition (or suspicion) of NSTEMI and continued for at least 48 hours to hospital discharge and/or until symptoms abide and objective markers demonstrate a trend towards normal.
                     <span class="reference"> 
                     <a href="#referencePop93" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[93]</a> 
                     <span class="citationText" aria-hidden="true">Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, et al. Heparin versus placebo for non-ST elevation acute coronary syndromes. Cochrane Database Syst Rev. 2014 Jun 27;(6):CD003462.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003462.pub3/full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24972265?tool=bestpractice.com
                     </span>
                     </span>
                     Agents include subcutaneous LMWH, intravenous UFH, or fondaparinux, according to clinician choice.
                  </p>
               </section>
               <section>
                  <h3>Long-term management post-stabilisation</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Long-term therapy consists of a range of pharmacological and non-pharmacological strategies. Cardiac rehabilitation is a structured programme that provides heart attack survivors with the tools, motivation, and support needed to change behaviour and increase chance of survival. Typically, cardiac rehabilitation programmes use group therapy to supervise and promote beneficial exercise, as well as to provide emotional support. The aims of cardiac rehabilitation are to:
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Increase functional capacity
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Stop cigarette smoking
                        </p>
                     </li>
                  </ul>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Modify lipids and lipoproteins
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Decrease body weight and fat stores
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Reduce BP
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Improve psychosocial well-being
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Prevent progression and promote plaque stability
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Restore and maintain optimal physical, psychological, emotional, social, and vocational functioning.
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Cardiac rehabilitation should be started on discharge and after clearance by an outpatient physician. The basic prescription should include aerobic and weight-bearing exercise 4 to 5 times per week for &gt;30 minutes.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                     [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                     </a>
                     <span class="ccaTitle" aria-hidden="true">What are the effects of exercise-based cardiac rehabilitation in people with coronary heart disease?</span>
                     <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1187/full</span>
                     <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                     </span>
                     There is a risk of triggering a recurrent MI with physical activity. However, this is minimal and reduced by using a structured programme to minimise (and treat) this risk.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Pharmacological strategies include the following.
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Aspirin should be continued indefinitely at a low dose if the patient is tolerant and not contraindicated.
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           A P2Y12 receptor inhibitor should be continued for up to 12 months. For patients with aspirin allergy, long-term P2Y12 receptor inhibitor use is suggested.
                           <span class="reference"> 
                           <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                           <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.onlinejacc.org/content/64/24/e139
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop94" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[94]</a> 
                           <span class="citationText" aria-hidden="true">Becker RC, Meade TW, Berger PB, et al; American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 Jun;133(6 Suppl):776-814S.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18574278?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop95" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[95]</a> 
                           <span class="citationText" aria-hidden="true">Harrington RA, Becker RC, Cannon CP, et al; American College of Chest Physicians. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 Jun;133(6 Suppl):670-707S.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18574276?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Oral beta-blockers should be continued indefinitely, especially in patients with reduced left ventricular function. Cardioselective beta-blockers are preferred in the initial management of NSTEMI, but guidelines recommend metoprolol, bisoprolol, or carvedilol for post-NSTEMI management in patients with stabilised heart failure and reduced systolic function.
                           <span class="reference"> 
                           <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                           <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.onlinejacc.org/content/64/24/e139
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           All patients with NSTEMI should start high-intensity statin therapy (moderate-intensity if not a candidate for high-intensity statin) in hospital regardless of cholesterol levels, and if there are no contraindications.
                           <span class="reference">
                              <a href="#referencePop96" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[96]</a> 
                              <span class="citationText" aria-hidden="true">Stone NJ, Robinson J, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.ahajournals.org/doi/full/10.1161/01.cir
                                 <rc-c2d-number data-rc-number=".0000437738">.0000437738</rc-c2d-number>
                                 .63853.7a
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24222016?tool=bestpractice.com
                              </span>
                           </span>
                           Two trials demonstrated superior outcomes in patients treated with atorvastatin within 12 hours of receiving PCI, and it may provide benefit when given early in NSTEMI.
                           <span class="reference"> 
                           <a href="#referencePop97" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[97]</a> 
                           <span class="citationText" aria-hidden="true">Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009 Dec 1;54(23):2157-63.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/19664895?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop98" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[98]</a> 
                           <span class="citationText" aria-hidden="true">Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009 Aug 4;54(6):558-65.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/19643320?tool=bestpractice.com
                           </span>
                           </span>
                           A high-intensity statin is defined as a daily dose that lowers low-density lipoprotein cholesterol (LDL-C) by approximately &gt;50%, while a moderate-intensity statin daily dose lowers LDL-C by approximately 30% to 50%. Statin therapy is particularly important in patients who have hyperlipidaemia, diabetes, prior MI, or CAD. Statins inhibit the rate-limiting step in cholesterol synthesis. They may also reduce vascular inflammation, improve endothelial function, and decrease thrombus formation in addition to lowering LDL.
                           <span class="reference">
                              <a href="#referencePop21" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[21]</a> 
                              <span class="citationText" aria-hidden="true">Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1524-34.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.ahajournals.org/doi/full/10.1161/01.atv
                                 <rc-c2d-number data-rc-number=".0000032033">.0000032033</rc-c2d-number>
                                 .39301.6a
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/12377727?tool=bestpractice.com
                              </span>
                           </span>
                           The addition of ezetimibe to the statin regimen may also be considered to achieve lower LDL targets and has a modest decrease in combined cardiovascular outcomes primarily driven by differences in non-fatal MI.
                           <span class="reference"> 
                           <a href="#referencePop20" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[20]</a> 
                           <span class="citationText" aria-hidden="true">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.nejm.org/doi/full/10.1056/NEJMoa1410489
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/26039521?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop99" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[99]</a> 
                           <span class="citationText" aria-hidden="true">Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicentre randomized controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015 Aug 4;66(5):495-507.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/26227186?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           The addition of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors, alirocumab and evolocumab, to maximally tolerated statin therapy may also be considered for patients who require additional LDL lowering (&lt;50% reduction in LDL-C; may also consider if LDL-C ≥2.59 mmol/L [≥100 mg/dL]).
                           <span class="reference"> 
                           <a href="#referencePop100" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[100]</a> 
                           <span class="citationText" aria-hidden="true">Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-22.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/28304224?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                           <span class="citationText" aria-hidden="true">Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 Jul 5;68(1):92-125.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.onlinejacc.org/content/68/1/92
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/27046161?tool=bestpractice.com
                           </span>
                           </span>
                           Alirocumab is approved for use as adjunct therapy to diet and maximally tolerated statin therapy for adult patients with heterozygous familial hypercholesterolaemia, or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL. Evolocumab is approved as an adjunct to diet and other lipid-lowering therapies (e.g., statins, ezetimibe) in patients with primary hyperlipidaemia (including heterozygous hypercholesterolaemia) and homozygous familial hypercholesterolaemia to reduce LDL. It is now also approved to reduce the risk of MI in patients with established cardiovascular disease, and may be used for this indication without adjunctive diet and lipid-lowering therapies. Evolocumab and alirocumab may also be used as an alternative to statins if they are contraindicated or the patient is intolerant of statins.
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           ACE inhibitors should be started in all patients with left ventricular systolic dysfunction (ejection fraction &lt;40%), heart failure, hypertension, diabetes, stable chronic kidney disease, or other high-risk features, such as ongoing ischaemia with worsening heart failure, S3 gallop, new or worsening mitral regurgitation, or haemodynamic instability, without overt cardiogenic shock.
                           <span class="reference"> 
                           <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                           <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.onlinejacc.org/content/64/24/e139
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                           <span class="citationText" aria-hidden="true">Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/37/3/267/2466099
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/26320110?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop102" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[102]</a> 
                           <span class="citationText" aria-hidden="true">Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005 Jun 15;293(23):2908-17.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/15956636?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop103" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[103]</a> 
                           <span class="citationText" aria-hidden="true">Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21;344(25):1879-87.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.nejm.org/doi/full/10.1056/NEJM200106213442501
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/11419424?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop104" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[104]</a> 
                           <span class="citationText" aria-hidden="true">Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006 Oct 3;48(7):1319-25.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.onlinejacc.org/content/48/7/1319.full
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/17010789?tool=bestpractice.com
                           </span>
                           </span>
                           They are started after 24 hours. The goal blood pressure is at least &lt;140/90 mmHg (including patients with chronic kidney disease or diabetes).
                           <span class="reference"> 
                           <a href="#referencePop105" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[105]</a> 
                           <span class="citationText" aria-hidden="true">James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://jamanetwork.com/journals/jama/fullarticle/1791497
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/24352797?tool=bestpractice.com
                           </span>
                           </span>
                           Angiotensin-II receptor antagonists may be used if the patient is intolerant to an ACE inhibitor.
                           <span class="reference">
                              <a href="#referencePop106" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[106]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13;349(20)
                                 <rc-c2d-number data-rc-number=":1893-906">:1893-906</rc-c2d-number>
                                 .
                              </span>
                              <span class="citationFullTextUrl" aria-hidden="true">
                              https://www.nejm.org/doi/full/10.1056/NEJMoa032292
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/14610160?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop107" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[107]</a> 
                           <span class="citationText" aria-hidden="true">Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 Sep 6;362(9386):772-6.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/13678870?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Aldosterone antagonists (e.g., eplerenone, spironolactone) should be used in all patients with left ventricular dysfunction (ejection fraction ≤40%), a history of diabetes mellitus, or evidence of congestive heart failure (S3 gallop, rales). They should be started in patients receiving target doses of ACE inhibitors or angiotensin-II receptor antagonists. Aldosterone blockade should not be used in patients with serum creatinine &gt;221 micromol/L (2.5 mg/dL) in men or &gt;177 micromol/L (2.0 mg/dL) in women, as well as in patients with hyperkalaemia (potassium &gt;5.0 mmol/L [5.0 mEq/L]).
                           <span class="reference"> 
                           <a href="#referencePop108" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[108]</a> 
                           <span class="citationText" aria-hidden="true">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.nejm.org/doi/full/10.1056/NEJMoa030207
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/12668699?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Oral anticoagulation may be indicated at discharge in selected patients with NSTEMI who are considered to be high risk for recurrent thrombosis. Several new medications, particularly direct thrombin inhibitors such as dabigatran and factor Xa inhibitors such as rivaroxaban and apixaban, are currently being evaluated as potential alternatives to warfarin.
                           <span class="reference">
                              <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                              <span class="citationText" aria-hidden="true">Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011 Oct;72(4):581-92. [Erratum in: Br J Clin Pharmacol. 2011 Oct;72(4):718.]</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j
                                 <rc-c2d-number data-rc-number=".1365-2125">.1365-2125</rc-c2d-number>
                                 .2011.03916.x
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/21241354?tool=bestpractice.com
                              </span>
                           </span>
                           While direct thrombin and factor Xa inhibitors may produce a modest reduction in ischaemic events when added to antiplatelet therapy, results also suggest that they increase the risk of major bleeding, particularly when added to dual antiplatelet therapy with aspirin and clopidogrel.
                           <span class="reference"> 
                           <a href="#referencePop110" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[110]</a> 
                           <span class="citationText" aria-hidden="true">Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013 Jun;34(22):1670-80.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/34/22/1670/502295
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23470494?tool=bestpractice.com
                           </span>
                           </span>
                           Low-dose rivaroxaban has been demonstrated to reduce future cardiovascular events but causes an almost equivalent increase in major bleeding events.
                           <span class="reference"> 
                           <a href="#referencePop111" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[111]</a> 
                           <span class="citationText" aria-hidden="true">Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366(1):9-19.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.nejm.org/doi/10.1056/NEJMoa1112277
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/22077192?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop112" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[112]</a> 
                           <span class="citationText" aria-hidden="true">Mega JL, Braunwald E, Wiviott SD, et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). Am J Cardiol. 2013 Aug 15;112(4):472-8.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23711804?tool=bestpractice.com
                           </span>
                           </span>
                           It has been approved in some countries, although not in the US.
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Triple antithrombotic therapy should be kept to as short a duration as clinically feasible for the patient, with full-dose oral anticoagulant indication after stent placement/acute coronary syndrome event.
                           <span class="reference"> 
                           <a href="#referencePop113" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[113]</a> 
                           <span class="citationText" aria-hidden="true">Lip GY, Collet JP, Haude M, et al. Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI. Eur Heart J. 2018 Aug 14;39(31):2847-50.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/39/31/2847/5076806
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/30137444?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop114" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[114]</a> 
                           <span class="citationText" aria-hidden="true">Dewilde WJ, Oirbans T, Verheugt FW, et al; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Mar 30;381(9872):1107-15.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23415013?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                  </ul>
               </section>
            </div>
         </div>
         <div class="card-block disclaimer">
            <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
         </div>
      </main>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd id="footerLogout">
                           <form method="POST" action="https://bestpractice.bmj.com/logout" role="menuitem">
                              <input type="hidden" name="loggedIn" id="loggedIn" value="true">
                              <button type="submit" value="Log out">Log out</button>
                           </form>
                        </dd>
                        <dd>                        
                           <a href="https://myaccount.bmj.com/myaccount/account/home-view.html?fwdUrl=https://bestpractice.bmj.com" target="_blank">
                           My details
                           </a>  
                        </dd>
                        <dd hidden="hidden">           
                           <a href="https://myaccount.bmj.com/myaccount/account/home-view.html#email-matrix-container?fwdUrl=https://bestpractice.bmj.com" target="_blank">
                           My emails
                           </a>  
                        </dd>
                        <dd><a href="https://bestpractice.bmj.com/activity">CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn">
                     <small>
                        ISSN
                        <rc-c2d-number data-rc-number=" 2515-9615"> 2515-9615</rc-c2d-number>
                     </small>
                  </p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">
         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="stailor@bmj.com">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: Non-ST-elevation myocardial infarction - Approach | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="Non-ST-elevation myocardial infarction - Approach | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p>
                                       <b>Phone:</b> 
                                       <rc-c2d-number data-rc-number="+44 (0) 207 111 1105">+44 (0) 207 111 1105</rc-c2d-number>
                                    </p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/151/management-approach#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../js/common.js"></script>
      <script type="text/javascript" src="../js/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 151;
           var topicLang = "en-gb";
           var topicTitle = "Non-ST-elevation myocardial infarction";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      <script type="text/javascript">
         _linkedin_data_partner_id = "103646";
      </script>
      <script type="text/javascript">
         (function()
         {var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);}
         )();
      </script>
      <script type="text/javascript" data-cfasync="false">
         (function(W,i,s,e,P,o,p){W['WisePopsObject']=P;W[P]=W[P]||function()
         { (W[P].q=W[P].q||[]).push(arguments)}
         ,W[P].l=1*new Date();o=i.createElement(s),
         p=i.getElementsByTagName(s)[0];o.async=1;o.src=e;p.parentNode.insertBefore(o,p)
         })(window,document,'script','//loader.wisepops.com/get-loader.js?v=1&site=qudyiEfMBd','wisepops');
         window.WisePopsLoaderCallback = function(wisepops) {
                         wisepops._storage.visits = wisepops._storage.visits.slice(0, 2);
                         wisepops._storage._saveVisits();
                       };
      </script>
      <noscript>
         <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=103646&fmt=gif" />
      </noscript>
      <!--[if lte IE 7]><script>var isIE7OrOlder = true; </script><![endif]-->   
      <!--[if lte IE 9]><script type="text/javascript" src="/gzip_e7393341757851d76c3264b590cf5143/js/browserupdate.js" ></script>
      <![endif]-->
      <script src="../js/adsct.js" type="text/javascript"></script><script type="text/javascript" id="createCookie">(function(){var b="bestpractice.bmj.com\/topics\/en-gb\/151\/management-approach",a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};a("RefTrack",b,2);a("RefTrackGroup","bestpractice.bmj.com",2)})();</script><script type="text/javascript" id="copyText">function getSelectionText(){var a="";window.getSelection?a=window.getSelection().toString():document.selection&&"Control"!=document.selection.type&&(a=document.selection.createRange().text);return a}document.addEventListener("copy",function(a){dataLayer.push({event:"textCopied",clipboardText:getSelectionText(),clipboardLength:getSelectionText().length})});</script>
      <script type="text/javascript" id="facebookPixel">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","414393182248444");fbq("track","PageView");</script>
      <noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=414393182248444&amp;ev=PageView&amp;noscript=1"></noscript>
      <button id="scrollTop" class="material-scrolltop" type="button"><span class="material-icons"></span></button>
      <rc-c2d-menu class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF">
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05">
            <img class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU" src="data:image/png;base64,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">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="Call with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 24 26">
                  <path fill="#0083BF" fill-rule="evenodd" stroke="#0684BD" stroke-width=".9" d="M6.656 17.651C.942 10.547.28 4.627 2.545 2.607c.592-.522 2.16-1.323 2.892-1.427.801-.14 1.602.243 2.02 1.01.802 1.636 1.777 3.238 2.788 4.805.452.697.348 1.567-.244 2.16-.349.348-.767.557-1.15.765a3.18 3.18 0 0 0-.801.523s-.105.104-.105.313c-.035.453.035 1.707 2.02 4.214 2.16 2.647 3.45 2.82 3.798 2.82.14 0 .244-.034.244-.034.244-.21.453-.453.662-.697.314-.348.593-.696 1.01-.975.697-.452 1.638-.348 2.16.21 1.325 1.323 2.753 2.576 4.112 3.76.662.557.906 1.428.557 2.16-.244.66-1.359 2.02-2.02 2.541-.558.488-1.324.697-2.195.697-3.345 0-7.7-2.925-11.637-7.8z"></path>
               </svg>
            </div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v"></div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="SMS with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 22 21">
                  <path fill="#0684BD" fill-rule="nonzero" d="M10.944.014C4.91.014.007 4.068.007 9.316c0 2.86 1.54 5.626 4.085 7.417-.094.534-.377 1.257-1.162 2.64l-.692 1.131h1.383a6.976 6.976 0 0 0 4.84-1.917c.817.157 1.634.252 2.483.252 6.034 0 10.936-4.275 10.936-9.523 0-5.28-4.902-9.302-10.936-9.302z"></path>
               </svg>
            </div>
         </div>
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO"></div>
         </div>
      </rc-c2d-menu>
      <script src="../js/saved_resource.js" type="text/javascript"></script>
   </body>
</html>